Abstract

The anticancer activities 3-(substituted phenyl)-1-[4-(morpholine-4-yl)phenyl]prop-2-en-1-one derivatives were investigated against PC3 (Human Prostate Carcinoma Cell) and HT29 (Human colon colorectal adenocarcinoma) cell lines. The anticancer activity tests were performed by the BrdU ELISA method. 5-Fluorouracil (5-FU) was used as standard compound. Compound 1-7 (except Compound 3) were determined to have higher anticancer activity than 5-FU aganist PC3 cancer cells. IC50 values of the Compounds 1-7 against PC3 cancer cells were 2.53±0.02 µM; 4.40±0.03 µM; 4.36±0.03 µM; 1.76±0.02 µM; 1.78±0.03 µM; 2.31±0.03 µM, respectively.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.